Compare CWH & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CWH | URGN |
|---|---|---|
| Founded | 1966 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 922.1M |
| IPO Year | 2016 | 2016 |
| Metric | CWH | URGN |
|---|---|---|
| Price | $6.58 | $18.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $15.89 | ★ $29.29 |
| AVG Volume (30 Days) | ★ 3.2M | 716.7K |
| Earning Date | 04-28-2026 | 03-02-2026 |
| Dividend Yield | ★ 7.32% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.99 | N/A |
| Revenue | ★ $4,792,017,000.00 | $1,128,000.00 |
| Revenue This Year | $4.63 | $127.17 |
| Revenue Next Year | $5.85 | $73.82 |
| P/E Ratio | $1.71 | ★ N/A |
| Revenue Growth | ★ 11.83 | N/A |
| 52 Week Low | $5.70 | $3.42 |
| 52 Week High | $19.64 | $30.00 |
| Indicator | CWH | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.82 | 50.93 |
| Support Level | $5.70 | $18.37 |
| Resistance Level | $18.18 | $20.44 |
| Average True Range (ATR) | 0.43 | 0.93 |
| MACD | 0.23 | 0.09 |
| Stochastic Oscillator | 71.43 | 87.80 |
Camping World Holdings Inc is a retailer of RVs and related products and services. The company has two reportable segments; the Good Sam Services and Plans segment, which includes the sale of emergency roadside assistance plans; commissions on property and casualty insurance programs; travel assist programs; extended vehicle service contracts; vehicle financing and refinancing assistance; consumer shows and events; and consumer publications and directories; and the RV and Outdoor Retail segment, which generates maximum revenue and includes the sale of new and used RVs; commissions on the finance and insurance contracts related to the sale of RVs; the sale of RV service and collision work; the sale of RV parts, accessories, business to business distribution of RV furniture, etc.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.